Perforation and Stage-II Colon Cancer: Is it Always High Risk?

Por Blanke, Charles D.
Publicado em 2008

Commentary: Clinical Trials Represent the Best Cancer Care. Or Do They?

Por Blanke, Charles D.
Publicado em 2011

Gastrointestinal oncology a practical guide /

Por Blanke, Charles D., Rödel, Claus., Talamonti, Mark S.
Publicado em 2011

Accomplishments in 2008 in the Management of Gastrointestinal Stromal Tumors

Por Renouf, Daniel, Blay, Jean-Yves, Blanke, Charles
Publicado em 2009

Effect of M1a and M1b Category in Metastatic Colorectal Cancer

Por Kennecke, Hagen, Yu, Jason, Gill, Sharlene, Cheung, Winson Y., Blanke, Charles D., Speers, Caroline, Woods, Ryan
Publicado em 2014

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415)

Por Gold, Philip J., Goldman, Bryan, Iqbal, Syma, Leichman, Lawrence P., Zhang, Wu, Lenz, Heinz-Josef, Blanke, Charles D.
Publicado em 2010

The Scientific Impact of Positive and Negative Phase III Cancer Clinical Trials

Por Unger, Joseph M., Barlow, Willliam E., Ramsey, Scott D., LeBlanc, Michael, Blanke, Charles D., Hershman, Dawn L.
Publicado no JAMA Oncol (2016)

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors

Por Blanke, Charles D., Rankin, Cathy, Corless, Christopher, Eary, Janet F., Mulder, Karen, Okuno, Scott H., George, Suzanne, Heinrich, Michael
Publicado no Oncologist (2015)

Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients Findings from CALGB 89803 and 80405

Por Van Loon, Katherine, Wigler, Devin, Niedzwiecki, Donna, Venook, Alan, Fuchs, Charles, Blanke, Charles, Saltz, Leonard, Goldberg, Richard M., Meyerhardt, Jeffrey A.
Publicado em 2013

KRAS and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice

Por Blanke, Charles D., Goldberg, Richard M., Grothey, Axel, Mooney, Margaret, Roach, Nancy, Saltz, Leonard B., Welch, John J., Wood, William A., Meropol, Neal J.
Publicado em 2011

Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials

Por Blanke, Charles D., Bot, Brian M., Thomas, David M., Bleyer, Archie, Kohne, Claus-Henning, Seymour, Matthew T., de Gramont, Aimery, Goldberg, Richard M., Sargent, Daniel J.
Publicado no J Clin Oncol (2011)

S9511: A Southwest Oncology Group Phase II Study of Trimetrexate, 5FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach

Por Blanke, Charles D., Chansky, Kari, Christman, Kathy L., Hundahl, Scott A., Issell, Brian F., Van Veldhuizen, Peter J., Budd, G Thomas, Abbruzzese, James L., Macdonald, John S.
Publicado em 2010

Phase II Trial of Depsipeptide (NSC-630176) in Previously Treated Colorectal Cancer Patients with Advanced Disease: A Southwest Oncology Group Study (S0336)

Por Whitehead, Robert P., Rankin, Cathryn, Hoff, Paulo M.G., Gold, Philip J., Billingsley, Kevin G., Chapman, Robert A., Wong, Lucas, Ward, John H., Blanke, Charles D.
Publicado em 2008

SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Por El-Khoueiry, Anthony B., Rankin, Cathryn J., Ben-Josef, Edgar, Lenz, Heinz-Josef, Gold, Philip J., Hamilton, R. Darryl, Govindarajan, Rangaswamy, Eng, Cathy, Blanke, Charles D.
Publicado em 2011

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group Study S0202

Por Iqbal, Syma, Rankin, Cathryn, Lenz, Heinz-Josef, Gold, Philip J., Ahmad, Syed A., El-Khoueiry, Anthony B., Messino, Michael J., Holcombe, Randall F., Blanke, Charles D.
Publicado em 2011

Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set

Por Hubbard, Joleen, Thomas, David M., Yothers, Greg, Green, Erin, Blanke, Charles, O'Connell, Michael J., Labianca, Roberto, Shi, Qian, Bleyer, Archie, de Gramont, Aimery, Sargent, Daniel
Publicado em 2012

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Metastatic Prostate Cancer Patients

Por Hershman, Dawn L., Unger, Joseph M., Wright, Jason D., Ramsey, Scott, Till, Cathee, Tangen, Catherine M., Barlow, William E., Blanke, Charles, Thompson, Ian M, Hussain, Maha
Publicado no JAMA Oncol (2016)

Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0...

Por Eisenberg, Burton L., Harris, Jonathan, Blanke, Charles, Demetri, George D., Heinrich, Michael C., Watson, James C., Hoffman, John P., Okuno, Scott, Kane, John M., von Mehren, Margaret
Publicado em 2009

Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304)

Por Ulrich, Cornelia M., Rankin, Cathryn, Toriola, Adetunji T., Makar, Karen W., Altug-Teber, Özge, Benedetti, Jacqueline K., Holmes, Rebecca S., Smalley, Stephen R., Blanke, Charles D., Lenz, Heinz-Josef
Publicado no Cancer (2014)

Gene Expression Signatures and Response to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Por Rink, Lori, Skorobogatko, Yuliya, Kossenkov, Andrew, Belinsky, Martin G., Pajak, Thomas, Heinrich, Michael C., Blanke, Charles D., von Mehren, Margaret, Ochs, Michael F., Eisenberg, Burton, Godwin, Andrew K.
Publicado em 2009